KCB Pharma Limited 12361263 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is Other human health activities Digita Accounts Production Advanced 6.30.9574.0 true 12361263 2023-04-01 2024-03-31 12361263 2024-03-31 12361263 core:CurrentFinancialInstruments 2024-03-31 12361263 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 12361263 core:OfficeEquipment 2024-03-31 12361263 core:PlantMachinery 2024-03-31 12361263 bus:SmallEntities 2023-04-01 2024-03-31 12361263 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 12361263 bus:FullAccounts 2023-04-01 2024-03-31 12361263 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 12361263 bus:RegisteredOffice 2023-04-01 2024-03-31 12361263 bus:Director1 2023-04-01 2024-03-31 12361263 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 12361263 core:OfficeEquipment 2023-04-01 2024-03-31 12361263 core:PlantMachinery 2023-04-01 2024-03-31 12361263 countries:AllCountries 2023-04-01 2024-03-31 12361263 2023-03-31 12361263 core:OfficeEquipment 2023-03-31 12361263 core:PlantMachinery 2023-03-31 12361263 2022-01-01 2023-03-31 12361263 2023-03-31 12361263 core:CurrentFinancialInstruments 2023-03-31 12361263 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 12361263 core:OfficeEquipment 2023-03-31 12361263 core:PlantMachinery 2023-03-31 iso4217:GBP xbrli:pure

Registration number: 12361263

KCB Pharma Limited

Unaudited Financial Statements

for the Year Ended 31 March 2024

 

KCB Pharma Limited

Contents

Balance Sheet

1 to 2

Notes to the Unaudited Financial Statements

3 to 5

 

KCB Pharma Limited

(Registration number: 12361263)

Balance Sheet as at 31 March 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

3

1,991

2,879

Current assets

 

Stocks

4

-

1,028

Debtors

5

22,515

6,868

Cash at bank and in hand

 

2

3,647

 

22,517

11,543

Creditors: Amounts falling due within one year

6

(24,354)

(13,922)

Net current liabilities

 

(1,837)

(2,379)

Net assets

 

154

500

Capital and reserves

 

Called up share capital

120

120

Profit and loss account

34

380

Shareholders' funds

 

154

500

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

 

KCB Pharma Limited

(Registration number: 12361263)

Balance Sheet as at 31 March 2024

These financial statements, which have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with the provisions of FRS 102 Section 1A Small Entities, were approved and authorised for issue by the director on 20 January 2025
 

.........................................

Mrs K Coddington-Bishop
Director

 

KCB Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

1

Accounting policies

KCB Pharma Limited is a private company, limited by shares, domiciled in England and Wales, company number 12361263. The registered office is at 22 Dentons Green Lane, Kirk Sandall, Doncaster, South Yorkshire, DN3 1JP, United Kingdom.

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value. The presentation currency is United Kingdom pounds sterling, which is the functional currency of the company. The financial statements are those of an individual entity.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in the statement of income and retained earnings, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

20% Straight Line

Plant and machinery

20% Straight Line

 

KCB Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in the statement of income and retained earnings.

2

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

3

Tangible assets

Plant and machinery
£

Office equipment
£

Total
£

Cost

At 1 April 2023

3,029

1,410

4,439

At 31 March 2024

3,029

1,410

4,439

Depreciation

At 1 April 2023

808

752

1,560

Charge for the year

606

282

888

At 31 March 2024

1,414

1,034

2,448

Carrying amount

At 31 March 2024

1,615

376

1,991

At 31 March 2023

2,221

658

2,879

4

Stocks

2024
£

2023
£

Other inventories

-

1,028

 

KCB Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

5

Debtors

2024
£

2023
£

Trade debtors

494

750

Prepayments

189

125

Other debtors

21,832

5,993

22,515

6,868

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Trade creditors

2,544

-

Corporation tax

19,620

11,822

Accruals and deferred income

2,190

2,100

24,354

13,922